<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02642458</url>
  </required_header>
  <id_info>
    <org_study_id>SEN2015-02</org_study_id>
    <nct_id>NCT02642458</nct_id>
  </id_info>
  <brief_title>Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients</brief_title>
  <acronym>PerFECT</acronym>
  <official_title>Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients: A Cohort Study of Patients Treated Either With Docetaxel and Trastuzumab or Docetaxel, Trastuzumab and Pertuzumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite the clear benefit of a combination therapy of pertuzumab plus trastuzumab plus
      docetaxel when compared with a combination therapy of trastuzumab and docetaxel the study
      populations of the CLEOPATRA trial might be slightly different from a patient population, in
      which pertuzumab, plus trastuzumab plus chemotherapy or trastuzumab plus chemotherapy are
      applied in routine clinical practice.

      This non-interventional approach aims to confirm the clinically relevant outcomes shown in
      the phase III CLEOPATRA study in patients with advanced HER2-positive breast cancer in
      routine practice. Docetaxel is recommended as chemotherapy, however, any treatment choice or
      change in regimen is performed at the discretion of the treating physician.

      Data on efficacy, safety, tolerability and quality of life will be documented for this
      purpose. Following the recommendations as laid down in guidelines for treatment of breast
      cancer, the quality of life of patients will be assessed on a regular basis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Breast cancer is the commonest cancer in women worldwide with an estimated 1.4 million new
      diagnoses in 2008 and 1.6 million cases estimated for 2015. In 2008 breast cancer was
      responsible for approximately 23% of all new cancer diagnoses in women. It is also the
      commonest cause of cancer deaths in women worldwide: in 2008 some 458,500 women died from
      breast cancer, with a further 538,500 projected for 2015.

      In developed countries most breast cancers (in 94%-95% of patients in the EU and USA) are
      diagnosed while the tumour is confined to the breast - with or without locoregional lymph
      node involvement. At this early breast cancer (EBC) stage the disease is normally operable
      and can be treated curatively. Metastatic breast cancer (MBC) is less common and occurs in
      5%-6% of newly diagnosed cases. Despite advances in the treatment of EBC approximately 30% of
      women develop local recurrence or metastases. In the USA and Europe patients with MBC survive
      for a mean 24 months and have a 5 year survival rate of 18%-23%.

      Between 18% and 20% of breast cancers show HER2 amplification and/or HER2 receptor
      overexpression. Such patients have a poor prognosis on conventional treatment. The HER2
      receptor is a protein belonging to the epidermal growth factor receptor (EGFR) family. The
      HER family consists of four structurally similar receptors - HER1/EGFR, HER2, HER3, HER4 -
      and regulates cell processes such as differentiation, invasion, proliferation,
      neoangiogenesis, survival and metastatic potential. In breast cancer HER2 positivity is
      associated with more aggressive tumours, higher relapse rates, lower and shorter treatment
      response and increased mortality.

      Systemic treatment options in MBC include chemotherapy along with hormonal and targeted
      approaches. Tumor properties and patient-specific factors determine the choice of treatment.

      In HER2-positive MBC trastuzumab for many years was the reference first-line treatment.
      Treatment-naive HER2-positive patients with MBC treated with trastuzumab and taxane
      chemotherapy showed significantly longer median time to progression (TTP), higher objective
      response rates (ORR) and longer median response and median survival than patients treated
      with chemotherapy alone. Although trastuzumab has proved effective in combination with
      chemotherapy in the first-line treatment of patients with HER2-positive MBC, approximately
      50% of patients experience disease progression within one year of starting treatment. Mean
      survival in HER2-positive patients in the pivotal studies of trastuzumab in combination with
      a taxane was 24.8 and 31.2 months.

      Therefore there is high medical need for novel HER2-targeted therapies to improve survival
      outcomes in patients with HER2-positive MBC.

      An essential step in activating downstream signalling pathways is homo or heterodimerisation
      of the HER2 receptor with the other member of the HER family. Inhibition of HER2 dimerisation
      inhibits the downstream signalling pathways that mediate cancer cell proliferation and
      survival. Pertuzumab, a humanised monoclonal antibody, is the first HER2 dimerisation
      inhibitor (HDI). It binds specifically to the extracellular dimerisation domain of the HER2
      receptor, thereby inhibiting ligand-dependent heterodimerisation of the receptor with other
      HER family members. Pertuzumab actually inhibits ligand-activated intracellular signal
      transduction in two main signalling pathways - the mitogen-activated protein kinase (MAPK)
      pathway and the phosphoinositide-3-kinase (PI3K) pathway. Inhibition of these signalling
      pathways can arrest cell growth and cause apoptosis. Pertuzumab also mediates
      antibody-dependent cell-mediated cytotoxicity (ADCC). Pertuzumab and trastuzumab bind to
      different epitopes on the HER2 receptor. Their mechanisms of action complement each other to
      ensure more comprehensive blockade of HER2-dependent signalling pathways.

      The phase III, multicentre, randomised, double-blind and placebo-controlled clinical
      CLEOPATRA trial compared pertuzumab plus trastuzumab plus docetaxel vs placebo plus
      trastuzumab plus docetaxel in 808 patients with HER2-positive metastatic, locally recurrentor
      inoperable breast cancer. Patients may have received one hormonal treatment for metastatic
      breast cancer before randomization. Patients may have received adjuvant or neoadjuvant
      chemotherapy with or without trastuzumab before randomization, with an interval of at least
      12 months between completion of the adjuvant or neoadjuvant therapy and the diagnosis of
      metastatic breast cancer. Randomised patients were stratified by previous treatment status
      (with or without previous adjuvant/neoadjuvant therapy) and geographic location (Europe,
      North America, South America and Asia). Pertuzumab was given intravenously at a starting dose
      of 840 mg followed by a dose of 420 mg every 3 weeks. Trastuzumab was given intravenously at
      a starting dose of 8 mg/kg followed by a dose of 6 mg/kg every 3 weeks. Patients were treated
      with pertuzumab plus trastuzumab until disease progression, withdrawal of consent to
      participation or the development of uncontrollable toxicity. Docetaxel was given as an
      intravenous infusion at a starting dose of 75 mg/m² every 3 weeks for at least 6 cycles. If
      the starting dose was well-tolerated, the dose of docetaxel could be increased up to 100
      mg/m² at the investigator's discretion.

      The primary study endpoint was progression-free survival (PFS), assessed by an independent
      review facility (IRF) and defined as the interval between randomisation and disease
      progression or death (from any cause), where death occurred within 18 weeks of the last
      disease assessment. The secondary endpoints were overall survival (OS), (investigator-rated)
      PFS, objective response rate (ORR), duration of response and time to progression (TTP).

      Demographic characteristics were evenly balanced (mean age was 54 years, most [59%] were
      Caucasian and all but two were female). In each treatment group approximately half the
      patients had hormone (estrogen or progesterone) receptor-positive disease and had received
      previous adjuvant or neoadjuvant therapy (184 patients [45.8%] in the pertuzumab group vs 192
      patients [47.3%] in the placebo group). Most (37.3% and 40.4%, respectively) had previously
      received anthracyclines and approximately 10% had previously received trastuzumab (11.7% and
      10.1%). A total 43% of patients from both groups had received prior radiotherapy. The mean
      baseline left ventricular ejection fraction (LVEF) was 64.8% in the pertuzumab group and
      65.6% in the placebo group (median 65.0%, range 50%-88% in the two groups).

      The CLEOPATRA study showed statistically significant improvement of IRF-rated PFS in the
      pertuzumab group vs placebo (hazard ratio [HR]=0.62; 95% CI=0.51; 0.75, p&lt;0.0001) and an
      increase in median PFS of 6.1 months. Median PFS was 18.5 months in the pertuzumab group vs
      12.4 months in the placebo group. Moreover, CLEOPATRA showed statistically significant
      improvement of overall survival in the pertuzumab group vs placebo (hazard ratio [HR]=0.68;
      95% CI=0.56; 0.84, p&lt;0.0002) and an increase in median OS of 15.7 months. Median OS was 56.5
      months in the pertuzumab group vs 40.8 months in the placebo group.

      Despite the clear benefit of a combination therapy of pertuzumab plus trastuzumab plus
      docetaxel when compared with a combination therapy of trastuzumab and docetaxel the study
      populations of the CLEOPATRA study might be slightly different from a patient population, in
      which pertuzumab, plus trastuzumab plus docetaxel or trastuzumab plus docetaxel are applied
      in routine clinical practice.

      This non-interventional approach aims to confirm the clinically relevant outcomes shown in
      the phase III CLEOPATRA study in patients with advanced HER2-positive breast cancer in
      routine practice. Data on efficacy, safety, tolerability and quality of life will be
      documented for this purpose.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival rate</measure>
    <time_frame>At 12 months or month 36</time_frame>
    <description>The primary objective of this study is to assess the progression free survival rate at month 12 for both treatment cohorts in routine clinical practice treated with either pertuzumab plus trastuzumab plus docetaxel or trastuzumab plus docetaxel.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Timepoint of progression or month 36</time_frame>
    <description>Progression free survival (PFS) is defined as the time interval from start of therapy until progression proven with clinical measures according to expertise and daily clinical routine or death from any cause, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Timepoint of progression or month 36</time_frame>
    <description>Overall response rate (ORR): Rate of complete (CR) and partial responses (PR) in patients. Response to treatment (CR, PR, SD, and PD) will be assessed by the treating physician and evaluated according to expertise and daily clinical routine. Underlying method of response assessment will be captured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (EORTC QLQ-C30)</measure>
    <time_frame>At 12 months</time_frame>
    <description>Quality of life (QoL) will be assessed by the EORTC QLQ-C30 (Version 3.0) within the first 12 months of first line treatment either with docetaxel and trastuzumab or docetaxel, trastuzumab and pertuzumab. The minimum target return rate for PRO questionnaires is 70% defined as at least 70% of patients having completed the PRO questionnaires at all collection time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events and serious adverse events will be documented</measure>
    <time_frame>up 36 month</time_frame>
    <description>Incidence of adverse events and serious adverse events will be reported according to NCI Common Toxicity Criteria Version 4.03.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (EORTC QLQ-BR23)</measure>
    <time_frame>At 12 months</time_frame>
    <description>Quality of life (QoL) will be assessed by the EORTC QLQ-BR23 (Version 1.0) within the first 12 months of first line treatment either with docetaxel and trastuzumab or docetaxel, trastuzumab and pertuzumab. The minimum target return rate for PRO questionnaires is 70% defined as at least 70% of patients having completed the PRO questionnaires at all collection time points.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>trastuzumab plus chemotherapy</arm_group_label>
    <description>Treatment with trastuzumab plus chemotherapie as first line therapy, administered intravenously/subcutaneously in a three weekly frequency. Docetaxel is recommended as chemotherapy, however, any treatment choice or change in regimen is performed at the discretion of the treating physician.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pertuzumab plus trastuzumab plus chemotherapy</arm_group_label>
    <description>Treatment with with pertuzumab plus trastuzumab plus chemotherapy as first line therapy, administered intravenously/subcutaneously in a three weekly frequency. Docetaxel is recommended as chemotherapy, however, any treatment choice or change in regimen is performed at the discretion of the treating physician.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study will be conducted as an open registry, therefore there will be no restriction in
        the number of patients to be included.

        The assignment of the patient to a particular treatment falls within current practice and
        the prescription of the medicine is clearly separated from the decision to include the
        patient in the non-interventional study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult breast cancer patients (age ≥18 years)

          -  Patients with metastatic or locally advanced, unresectable HER2-positive breast cancer
             proven by clinical measures (i.e. standard imaging) in first line treatment (Locally
             recurrent disease must not be amenable to resection with curative intent)

          -  Patients who are eligible for treatment with trastuzumab plus chemotherapy or
             pertuzumab plus trastuzumab plus chemotherapy as first line therapy, administered
             intravenously in a three weekly frequency, according to each center's medical
             practice. The first line anti-HER2 treatment must not have started more than 28 days
             before study entry.

          -  No prior chemotherapy or HER2-directed therapy for metastatic or locally advanced
             disease, prior therapy for early breast cancer (eBC) is allowed

          -  Signed informed consent prior to onset of documentation.

        Exclusion Criteria:

        • Patients who are not eligible for observation due to severe comorbidities or
        unavailability according to the treating physician
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diethelm Wallwiener, Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Universitätsfrauenklinik Tübingen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Fasching, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Frauenklinik des Universitätsklinikums Erlangen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sara Brucker, Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Universitätsklinikum Tübingen Universitäts-Frauenklinik</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erik Belleville, PhD</last_name>
    <phone>+49 931 359200</phone>
    <phone_ext>36</phone_ext>
    <email>belleville@clin-sol.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Klinikum für Frauenheilkunde und Geburtshilfe Esslingen</name>
      <address>
        <city>Esslingen</city>
        <state>Baden-Württemberg</state>
        <zip>73730</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg Klinik für Frauenheilkunde</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Württemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NCT Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Frauenklinik des Städtischen Klinikums</name>
      <address>
        <city>Karlsruhe</city>
        <state>Baden-Württemberg</state>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Vicentius Kliniken Karlsruhe gAG Frauenklininik</name>
      <address>
        <city>Karlsruhe</city>
        <state>Baden-Württemberg</state>
        <zip>76135</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ortenau Klinikum Lahr-Ettenheim</name>
      <address>
        <city>Lahr</city>
        <state>Baden-Württemberg</state>
        <zip>77993</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxisklinik am Rosengarten</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Württemberg</state>
        <zip>68165</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Mannheim, Universitäts-Frauenklinik</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Württemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>medius Klinik Nürtingen</name>
      <address>
        <city>Nürtingen</city>
        <state>Baden-Württemberg</state>
        <zip>72622</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Paracelsus Krankenhaus Ruit</name>
      <address>
        <city>Ruit</city>
        <state>Baden-Württemberg</state>
        <zip>73760</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>KlinikumStuttgart Olgahospital/ Frauenklinik</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Württemberg</state>
        <zip>70714</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik Tübingen</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>GRN-Klinik Weinheim</name>
      <address>
        <city>Weinheim</city>
        <state>Baden-Württemberg</state>
        <zip>69469</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkokom GbR</name>
      <address>
        <city>Altötting</city>
        <state>Bayern</state>
        <zip>84503</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MVZ Amberg</name>
      <address>
        <city>Amberg</city>
        <state>Bayern</state>
        <zip>92224</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>phase drei Hämato-Onkologischer Studienkreis am Klinikum Aschaffenburg</name>
      <address>
        <city>Aschaffenburg</city>
        <state>Bayern</state>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hämatologische-onkologische Praxis</name>
      <address>
        <city>Augsburg</city>
        <state>Bayern</state>
        <zip>86150</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Augsburg Frauenklinik</name>
      <address>
        <city>Augsburg</city>
        <state>Bayern</state>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinik für Frauenheilkunde und Geburtshilfe Klinikum Bayreuth GmbH</name>
      <address>
        <city>Bayreuth</city>
        <state>Bayern</state>
        <zip>95445</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rottal-Inn-Kliniken GmbH</name>
      <address>
        <city>Eggenfelden</city>
        <state>Bayern</state>
        <zip>84307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik Erlangen</name>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <zip>91012</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hämatologisch-Onkologische Praxis</name>
      <address>
        <city>Kronach</city>
        <state>Bayern</state>
        <zip>96317</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MOPS Elisenhof MOP-Studiengesellschaft</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>80335</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hämato-Onkologische Schwerpunktpraxis</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>80638</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg AöR</name>
      <address>
        <city>Nürnberg</city>
        <state>Bayern</state>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Schwerpunktpraxis für Gynäkologische Onkologie</name>
      <address>
        <city>Fürstenwalde</city>
        <state>Brandenburg</state>
        <zip>15517</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ärzteforum Brandenburg Praxis Dr. Andrea Speidel</name>
      <address>
        <city>Hennigsdorf</city>
        <state>Brandenburg</state>
        <zip>16761</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Ludwigsfelde-Teltow gGmbH</name>
      <address>
        <city>Ludwigsfelde</city>
        <state>Brandenburg</state>
        <zip>14947</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hochschulklinikum der Med. Hochschule Brandenburg</name>
      <address>
        <city>Neuruppin</city>
        <state>Brandenburg</state>
        <zip>16816</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>g.SUND Gynäkologie Kompetenzzentrum</name>
      <address>
        <city>Stralsund</city>
        <state>Brandenburg</state>
        <zip>18435</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Darmstadt, Frauenklinik</name>
      <address>
        <city>Darmstadt</city>
        <state>Hessen</state>
        <zip>64283</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zentrum für Hämatologie und Onkologie Bethanien</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MVZ Onkologische Kooperation Harz Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Goslar</city>
        <state>Hessen</state>
        <zip>38643</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Kassel GmbH Klinik für Frauenheilkunde und Geburtshilfe</name>
      <address>
        <city>Kassel</city>
        <state>Hessen</state>
        <zip>34125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Frauenklinik Wetzlar</name>
      <address>
        <city>Wetzlar</city>
        <state>Hessen</state>
        <zip>35578</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Agaplesion Diakonieklinikum Rotenburg/Wümme gGmbH</name>
      <address>
        <city>Rotenburg</city>
        <state>Niedersachsen</state>
        <zip>27356</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis f. Hämatologie u. Onkologie</name>
      <address>
        <city>Westerstede</city>
        <state>Niedersachsen</state>
        <zip>26655</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Facharztzentrum am Schloß</name>
      <address>
        <city>Wolfenbüttel</city>
        <state>Niedersachsen</state>
        <zip>38307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MarienHospital Onkologische Praxis</name>
      <address>
        <city>Bonn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>53115</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marienhospital Bottrop gGmbH</name>
      <address>
        <city>Bottrop</city>
        <state>Nordrhein-Westfalen</state>
        <zip>46236</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinik für Frauenheilkunde und Geburtshilfe des Universitätsklinikums Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <state>Nordrhein-Westfalen</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dokusan Gesellschaft für medizinische studien mbH &amp; Co .KG</name>
      <address>
        <city>Herne</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44623</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Krefeld</name>
      <address>
        <city>Krefeld</city>
        <state>Nordrhein-Westfalen</state>
        <zip>Krefeld</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut für Versorgungsforschung in der Onkologie</name>
      <address>
        <city>Köln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50679</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe des Universitätsklinikums Köln Brustzentrum</name>
      <address>
        <city>Köln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hämatologisch-Onkologische Praxis</name>
      <address>
        <city>Würselen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>52146</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Schwerpunktpraxis für Hämatologie und Onkologie Hansen/Reeb/Pfitzner-Dempfle/Stehle</name>
      <address>
        <city>Kaiserslautern</city>
        <state>Rheinland-Pfalz</state>
        <zip>67655</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut für Versorgungsforschung in der Onkologie</name>
      <address>
        <city>Koblenz</city>
        <state>Rheinland-Pfalz</state>
        <zip>56068</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hämatologisch-onkologische Schwerpunktpraxis</name>
      <address>
        <city>Mayen</city>
        <state>Rheinland-Pfalz</state>
        <zip>56727</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis</name>
      <address>
        <city>Halle (Saale)</city>
        <state>Sachsen-Anhalt</state>
        <zip>06110</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Chemnitz gGmbH Frauenklinik</name>
      <address>
        <city>Chemnitz</city>
        <state>Sachsen</state>
        <zip>09116</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Dr.med. Peter Jungberg</name>
      <address>
        <city>Chemnitz</city>
        <state>Sachsen</state>
        <zip>09117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkologische Gemeinschaftspraxis Dresden</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitäres Krebszentrum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>KKH Torgau</name>
      <address>
        <city>Torgau</city>
        <state>Sachsen</state>
        <zip>04860</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Christian-Albrecht-Universitäts Kiel</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24118</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gynäkologische Gemeinschaftspraxis</name>
      <address>
        <city>Berlin</city>
        <zip>10317</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MVZ Friedrichshain Onkologisches Versorgungszentrum</name>
      <address>
        <city>Berlin</city>
        <zip>10407</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkologisch-Hämatologische Schwerpunktpraxis</name>
      <address>
        <city>Bremen</city>
        <zip>28209</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gynäkologische Praxisklinik Harburg</name>
      <address>
        <city>Hamburg</city>
        <zip>21073</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2015</study_first_submitted>
  <study_first_submitted_qc>December 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2015</study_first_posted>
  <last_update_submitted>October 26, 2017</last_update_submitted>
  <last_update_submitted_qc>October 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

